Expert Interview
Third View: Discussing Sumitomo Pharma's FDA approval for GEMTESA (vibegron) for men with overactive bladder symptoms receiving pharmacological therapy for benign prostatic hyperplasia.
Ticker(s): DNPUFInstitution: Premier Medical Association
- Urologist with 30+ years of experience and has contributed to several articles regarding the latest developments in urology conditions and treatments and is the recipient of the American Urological Association Grand Prize for clinical research for work performed regarding bladder cancer.
- Manages 250 NMIBC patients
- Familiar with the latest results from BOND-003 Phase 3 Trial
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
